Home › Companies › CUE
Cue Biopharma
Market cap $23.7M 8.4M shares (10-Q, Nov 13, 2026) × $2.83 close Nov 17, 2026
Most recent annual filing: 2026-03-16
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- CUE-221 IND filing2H 2026CUE-221 IND filing, 2H 2026, material
- CUE-401 readout2H 2026/1H 2027CUE-401 readout, 2H 2026/1H 2027, material
- CUE-401 Ph1 startEnd of 2026CUE-401 Ph1 start, End of 2026, notable
- CUE-221 Ph2b start4Q 2026CUE-221 Ph2b start, 4Q 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (6 active programs)
CUE-401
CUE-501
- Undisclosed indication Preclinical Boehringer Ingelheim International
CUE-101
CUE-102
CUE-221
CUE-221
UB-221 · Ascendant-221 Technology platforms
Capital (as filed)
- Cash
- $57.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$10.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $57.9M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (3)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on Cue Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-20 Watch Cue Biopharma, Inc. (CUE) — Scientific Deep Dive for CUE-221 and Pipeline Products CUE-221 biology is real and the H2 2026 Phase 2 CSU readout is a legitimate binary catalyst, but the equity is a going-concern story with a punishing Ascendant change-of-control structure; track from the sidelines and re-evaluate after data.
- 2026-06-02 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The Horizon Crew Takes the Board The concentration of Horizon/AbbVie operators on a pruned five-person board is a real deal-prep signal that upgrades the team who will monetize the H2 2026 CSU binary, justifying a small speculative position.
- 2026-07-10 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The $50M Vote of Confidence and the CSU Clock Cormorant leading a $50M PIPE at $33.21 (3x the April mark) effectively neutralizes the going-concern risk and tightens the CSU readout to end of Q3 2026, maintaining the speculative buy with the binary now ~11 weeks out.
- 2026-07-13 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The CMO Chair Gets Filled, the PIPE Overhang Bites CMO hire completes the operator stack with 11 weeks to the binary, and the 15.9% pullback to near the institutional PIPE price offers a cleaner risk/reward without changing the fundamental setup.
- 2026-08-04 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The IND Nobody Noticed The food-allergy IND filing opens a US-controlled clinical path that partially answers the China-data-acceptance risk, while the CSU readout guidance holds at end-of-Q3 for a third consecutive disclosure.
- 2026-08-15 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - A $153 Million Loss That Isn't a Loss The going-concern doubt is functionally resolved via the Q2 10-Q's twelve-month sufficiency assertion, Driehaus joins the institutional register, and the China manufacturing carve-out improves regulatory hygiene, but the science and the coin flip are unchanged with ~6 weeks to the binary.
- 2026-08-22 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The CEO's 13D and the 30% Air Pocket The 29.9% drawdown is driven by PSU settlement mechanics, a mandatory sell-to-cover, and a new S-3 shelf — cap-table plumbing, not clinical news — leaving the speculative buy intact with ~6 weeks to the binary.
- 2026-09-22 Buy core UPDATE: Cue Biopharma (CUE) - The Coin Landed, and It Landed Off-Drug The Phase 2 CSU binary resolved favorably with a clean dose-response, a 46% UAS7=0 at the top dose versus 11% placebo, and a 36-point off-drug gap at Week 28 that validates the CD23 mechanism, substantially retiring clinical risk while structural risks (FDA acceptance of China data, $215M Ascendant acceleration, dilution) remain.
- 2026-11-17 Speculative buy speculative UPDATE: Cue Biopharma (CUE) - Half the Price, a Green Light, and a Tax Bill FDA-cleared food-allergy IND and high-IgE subgroup data advance the science, but effective cash is ~$46M after a $12.1M payroll-tax accrual, the CSU regulatory path remains unresolved, and a 50% post-upgrade drawdown with no disclosed negative catalyst warrants cutting conviction one notch back to speculative.
- Long call · opened Jun 3, 2026 at $26.91 · -89.5% vs XBI +11.9% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Phase 2 data readout in Chronic Spontaneous Urticaria anticipated by the end of the third quarter of 2026 CUE-401”
matched to CUE-221 · trial initiation
-
-
“Phase 2 data readout in Chronic Spontaneous Urticaria anticipated by the end of the third quarter of 2026 CUE-401”
matched to CUE-221 · trial initiation
-
-
“We are expecting to submit an Investigational New Drug, or IND, amendment to the U.S. Food and Drug Administration, or FDA, to expand development into food allergy in the second half of 2026.”
matched to CUE-221 · trial initiation
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (32)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Jul 9, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseCue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations · EX-99.1→ BD updateNew high-IgE subgroup data from the Phase 2 CSU study expand the food allergy commercial thesis, CUE-401 enters the clinic, Balyasny crosses 5% while the stock has cratered 50% from the data-day close — time to decode what's driving the drawdown and where the thesis stands.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Sep 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe binary the thesis was built on just fired: CUE-221's Phase 2 CSU data landed positive, with primary and key secondary endpoints met and a durability signal 12 weeks off-drug that omalizumab couldn't match — the first clinical evidence that the CD23 dual-MOA is real beyond a petri dish.BD extracted 1 program update from this document → CUE pipeline
- Sep 20, 2026ReleaseCue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria→ BD updateSummary on the 8-K of Sep 21, 2026
- Aug 21, 2026SCHEDULE 13DActivist / >5% holder (13D)→ BD updateThe July PIPE resale S-3 went effective August 20, freeing ~1.5M institutional shares into a 7.4M-share float — and the stock cratered 30% to $23.98. The CEO's 13D simultaneously reveals that the company sold 58,258 shares on her behalf for tax withholding, not a discretionary exit, and that her $33 PSU tranche already vested.
- Aug 14, 2026ReleaseCue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Aug 14, 20268-KCurrent report: results of operations · EX-99.1
- Aug 14, 202610-QQuarterly report
- Aug 12, 2026S-3Shelf registration
- Aug 3, 2026ReleaseCue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug SubmissionBD extracted 1 program update from this document → CUE pipeline
- Aug 3, 20268-KCurrent report: officer / director change
- Jul 13, 2026ReleaseCue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
- Jul 10, 20268-KCurrent report: material agreement, unregistered sale of equity, officer / director change · EX-99.1
- Jul 9, 2026ReleaseCue Biopharma Announces $50.0 Million Private Placement
- Jun 18, 2026S-3Shelf registration
- Jun 3, 2026S-3Shelf registration
- Jun 3, 20268-KCurrent report: officer / director change, shareholder vote
- Jun 2, 20268-KCurrent report: officer / director change, other events
- May 21, 2026DEF 14AProxy statement
- May 14, 20268-KCurrent report · EX-99.1
- May 14, 202610-QQuarterly report
- May 1, 20268-KCurrent report: material agreement, unregistered sale of equity, officer / director change · EX-99.1
- Apr 22, 20268-KCurrent report: holder rights modified, charter / bylaws / fiscal year
- Apr 13, 20268-KCurrent report: shareholder vote
- Apr 7, 20268-KCurrent report: other events
- Mar 27, 2026DEFA14AProxy soliciting material
- Mar 27, 20268-KCurrent report: officer / director change
- Mar 16, 2026S-3Shelf registration
- Mar 16, 2026DEF 14AProxy statement
- Mar 16, 20268-KCurrent report: results of operations · EX-99.1
- Mar 16, 202610-KAnnual report
25 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- Nov 10, 2026SCHEDULE 13G/A13G amendment
- Oct 8, 2026SCHEDULE 13G/A13G amendment
- Aug 20, 2026EFFECTRegistration effective
- Aug 18, 2026CORRESPCORRESP
- Aug 17, 2026UPLOADUPLOAD
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 22, 2026DForm D (exempt offering)
- Jul 1, 2026EFFECTRegistration effective
- Jun 29, 2026CORRESPCORRESP
- Jun 25, 2026UPLOADUPLOAD
- Jun 17, 2026EFFECTRegistration effective
- Jun 15, 2026CORRESPCORRESP
- Jun 10, 2026UPLOADUPLOAD
- Jun 3, 2026S-8Employee plan registration
- May 14, 2026DForm D (exempt offering)
- May 11, 2026PRE 14APRE 14A
- May 1, 2026S-8Employee plan registration
- Mar 31, 2026EFFECTRegistration effective
- Mar 27, 2026CORRESPCORRESP
- Mar 23, 2026UPLOADUPLOAD
- Mar 16, 2026ARSAnnual report to shareholders
- Mar 6, 2026PRE 14APRE 14A